OLA
GANX icon

Oliver Luxxe Assets’s Gain Therapeutics GANX Stock Holding History

Oliver Luxxe Assets’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.1K Hold
20,250
– – 0.01% 199
2026
Q1 		$39.3K Hold
20,250
– – 0.01% 200
2025
Q4 		$65.2K Buy
+20,250
New +$54K 0.01% 189

Other funds holding GANX

BFA
Benedict Financial Advisors Atlanta, Georgia $515M AUM 24.59% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Oliver Luxxe Assets's GANX Position: Q2 2026 in Review

Oliver Luxxe Assets held its Gain Therapeutics (GANX) position steady in Q2 2026 at 20,250 shares worth $41.1K. The position accounts for 0.01% of the portfolio, ranked #199.

Oliver Luxxe Assets first reported a position in GANX in Q4 2025 and has held it in 3 quarters since. The position peaked at $65.2K in Q4 2025. 3 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • Oliver Luxxe Assets held 20,250 shares of Gain Therapeutics worth $41.1K as of Q2 2026.
  • Oliver Luxxe Assets left its Gain Therapeutics share count unchanged in Q2 2026.
  • Gain Therapeutics made up 0.01% of Oliver Luxxe Assets's portfolio in Q2 2026, its #199 holding.
  • Oliver Luxxe Assets first reported a position in Gain Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Oliver Luxxe Assets's Gain Therapeutics position peaked at $65.2K in Q4 2025.
  • 3 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Oliver Luxxe Assets's 13F filing for Q2 2026, filed 9 Jul 2026.